(248) 520-2329
Select Page

Parents who have kids with the deltaF508 strain of cystic fibrosis will soon be able to breathe a little easier.

Results from the clinical trials by Vertex Pharmaceutical’s have stocks climbing. The drug company climbed 55 percent to $58.12 at the close of the New York trading on May 7th, 2012.

Click here to read the full article